Costimulation of T cells for tumor immunity

Immunol Today. 1993 Oct;14(10):483-6. doi: 10.1016/0167-5699(93)90262-J.


Tumor specific antigens can be demonstrated on many neoplasms by immunization and challenge experiments; however, these antigens do not normally elicit a sufficiently strong immune response to prevent tumor growth in immunocompetent hosts. Recent studies have demonstrated that efficient activation of T cells requires costimulation of the CD28 receptor via the B7 molecule on antigen-presenting cells. Inadequate costimulation of tumor-reactive T cells may contribute to the fact that antigenic tumors are not normally rejected by the immune system, and weak anti-tumor immune responses may be amplified by upregulation of CD28 triggering.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigens, Neoplasm
  • B7-1 Antigen
  • CD28 Antigens
  • Humans
  • Lymphocyte Activation
  • Models, Biological
  • Neoplasms, Experimental / immunology*
  • T-Lymphocytes / immunology*


  • Antigens, Neoplasm
  • B7-1 Antigen
  • CD28 Antigens